PATENT CLAIM ANALYSIS

Application Number: 15744251
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "04400A"]

Abstract:
The present invention aims to provide a novel nucleic acid capable of suppressing expression of β2GPI, as well as a pharmaceutical composition for the prophylaxis or treatment of diseases associated with β2GPI expression. The present invention solves the above-mentioned problem by providing an antisense oligonucleotide having a β2GPI expression suppressive activity, a pharmaceutical composition containing the antisense oligonucleotide, and a prophylactic or therapeutic drug for autoimmune diseases including APS, SLE and the like, and thrombosis in hemodialysis that contains the antisense oligonucleotide and suppresses β2GPI expression.

Claim (Index 1):
An antisense oligonucleotide consisting of 8-80 bases in length that suppresses an expression of \u03b22GPI, comprising a sequence hybridizable to a nucleic acid consisting of a base sequence shown in any of SEQ ID NOs: 201-399 under stringent conditions.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 86.0
- Lexical Diversity: 1.66071
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14647952', '15759267', '12344143', '14581485', '12743797']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7724702262526978
- 35 USC 102 Novelty (BERT): 0.4993889185243474
- Combined Prediction Score: 0.7451620954798628
- Mean Citation Score: 235.88230600000003
- Max Citation Score: 237.96382000000003
- Similarity Product: 164.22284956436158

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test